| |
 |
The Market Outlook for Research Products in FY2010
|
Report #09-006
Publication Date: October 2009
Page Count: 235
Print Copy: $3,200
Company-wide Electronic Copy (includes print copy): $5,200
plus Data Set: an additional $1,200
|
Each member of The Science Advisory Board who participated in this study was invited to comment on the following questions. The responses, which have been edited for grammar and clarity, appear below along with each respondent’s job position.
Question 40. How confident are you that the stimulus bills recently passed (within the last 12 to 24 months) in your country will benefit the life sciences in FY2010? In FY2011? For US respondents, please consider the ARRA when answering this question. (please specify for each)
FY2010
A little confident.
FY2011
More confident.
--Professor/United States
FY2010
Already having an effect.
FY2011
Should see conditions return to normal.
--Lab Director/United Kingdom
FY2010
Confident.
FY2011
Not convinced.
--Principal Investigator/United States
FY2010
For those who actually received the grants, quite a lot, but given that the
granting percent was quite low (1-2%) overall I think the effect will be
marginal. But it seems likely the main NIH budget won’t be cut, and may
even be increased, so that bodes well for the life sciences in the US.
FY2011
Same: For those who actually received the grants, quite a lot, but given that
the granting percent was quite low (1-2%) overall I think the effect will be
marginal. But it seems likely the main NIH budget won’t be cut, and may
even be increased, so that bodes well for the life sciences in the US.
--Staff Scientist/United States
FY2010
I think there will be big improvement in Q1 2010.
FY2011
I think that the recession will be over.
--Department Head/United Kingdom
FY2010
No effect in 2010 due to long lead-time of grant funded work.
FY2011
May see a reduced availability of funds due to reduced income for funding
bodies.
--Post Doctoral Fellow/United Kingdom
FY2010
Not at all confident. The funding mechanisms (ARRA) are too rapid and
arbitrary. Funding levels for ARRA were at the 2% level of applications
received.
FY2011
Worse than 2010. ARRA will expire. $8 billion to NIH Institutes will help, but
this is also a TEMPORARY fix.
--Principal Investigator/United States
FY2010
Not that confident. I do not foresee much improvement with ARRA in place.
FY2011
I think recovery will be slow and benefit will be moderate.
--Lab Director/United States
FY2010
The ARRA seems like a ‘quick fix’ that’s not going to change the overall
dismal funding opportunities for the majority of Life Science researchers. It
provides too little funds for too few investigators for too short of a period. All
it does is give the APPEARANCE that this govt. cares more about funding
research.
FY2011
I am not a private sector proponent by nature, but the weak support of
our govt. funding for any truly novel, non-mainstream research leads me
to believe that partnering w/ industry may be our best hope for research
funding opportunities once the recession begins to lift.
--Staff Scientist/United States
And many more..
|
|
